Seeking Alpha

Biogen Idec (BIIB) -5.8% after reporting the failure of its dexpramipexole drug for treating...

Biogen Idec (BIIB) -5.8% after reporting the failure of its dexpramipexole drug for treating people with amyotrophic lateral sclerosis (ALS), which is also known as Lou Gehrig's disease and which affects the nerve cells in the brain and spinal cord that control muscle movement. The medicine didn't meet its primary goals of improving "function and survival," nor did it meet any key secondary endpoints. (PR)
From other sites
Comments (2)
  • stevesko
    , contributor
    Comments (60) | Send Message
     
    Over reaction, they have a strong pipeline, and when doing drug discovery these things should be expected. It's not like it was BG-12 that failed, THAT would cause the stock to tank.
    3 Jan 2013, 08:58 AM Reply Like
  • hagof
    , contributor
    Comment (1) | Send Message
     
    My sister has MS and I have invested in BIIB while it was still Biogen.
    I am not ready to give up, some drugs will eventually be effective, research is a long term project.
    Hadwig (Chemist)
    3 Jan 2013, 11:36 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs